Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:116464701" >
An HIV-1 clade C DN...
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
-
Harari, A (författare)
-
Bart, PA (författare)
-
Stohr, WF (författare)
-
visa fler...
-
Tapia, G (författare)
-
Garcia, M (författare)
-
Medjitna-Rais, E (författare)
-
Burnet, S (författare)
-
Cellerai, C (författare)
-
Erlwein, O (författare)
-
Barber, T (författare)
-
Moog, C (författare)
-
- Liljestrom, P (författare)
- Karolinska Institutet
-
Wagner, R (författare)
-
Wolf, H (författare)
-
Kraehenbuhl, JP (författare)
-
Esteban, M (författare)
-
Heeney, J (författare)
-
Frachette, MJ (författare)
-
Tartaglia, J (författare)
-
McCormack, S (författare)
-
Babiker, A (författare)
-
Weber, J (författare)
-
Pantaleo, G (författare)
-
visa färre...
-
(creator_code:org_t)
- 2008-01-14
- 2008
- Engelska.
-
Ingår i: The Journal of experimental medicine. - : Rockefeller University Press. - 1540-9538 .- 0022-1007. ; 205:1, s. 63-77
- Relaterad länk:
-
http://jem.rupress.o...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive DNA C or nothing on day 0 and at week 4, followed by NYVAC C at weeks 20 and 24. The primary immunogenicity endpoints were measured at weeks 26 and 28 by the quantification of T cell responses using the interferon γ enzyme-linked immunospot assay. Our results indicate that the DNA C plus NYVAC C vaccine regimen was highly immunogenic, as indicated by the detection of T cell responses in 90% of vaccinees and was superior to responses induced by NYVAC C alone (33% of responders). The vaccine-induced T cell responses were (a) vigorous in the case of the env response (mean 480 spot-forming units/106 mononuclear cells at weeks 26/28), (b) polyfunctional for both CD4 and CD8 T cell responses, (c) broad (the average number of epitopes was 4.2 per responder), and (d) durable (T cell responses were present in 70% of vaccinees at week 72). The vaccine-induced T cell responses were strongest and most frequently directed against Env (91% of vaccines), but smaller responses against Gag-Pol-Nef were also observed in 48% of vaccinees. These results support the development of the poxvirus platform in the HIV vaccine field and the further clinical development of the DNA C plus NYVAC C vaccine regimen.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Harari, A
-
Bart, PA
-
Stohr, WF
-
Tapia, G
-
Garcia, M
-
Medjitna-Rais, E
-
visa fler...
-
Burnet, S
-
Cellerai, C
-
Erlwein, O
-
Barber, T
-
Moog, C
-
Liljestrom, P
-
Wagner, R
-
Wolf, H
-
Kraehenbuhl, JP
-
Esteban, M
-
Heeney, J
-
Frachette, MJ
-
Tartaglia, J
-
McCormack, S
-
Babiker, A
-
Weber, J
-
Pantaleo, G
-
visa färre...
- Artiklar i publikationen
-
The Journal of e ...
- Av lärosätet
-
Karolinska Institutet